Showing 931-940 of 1059 results for "".
- Treatment of RLS with Horizant Reduces Nighttime Agitation & Improves Sleep in Patients with Dementiahttps://practicalneurology.com/news/treatment-of-rls-with-horizant-reduces-nighttime-agitation-improves-sleep-in-patients-with-dementia/2470492/Study results showed improved sleep and a reduction in nighttime agitation in dementia patients with restless legs syndrome (RLS) treated with Horizant (gabapentin enacarbil; Azurity Pharmaceuticals, Woburn, MA). These results were presented at the 2024 SLEEP meeting of the Associated Professiona
- Low-Sodium Narcolepsy Treatment Safe & Effective in Patients with Cardiovascular/Cardiometabolic Comorbiditieshttps://practicalneurology.com/news/low-sodium-narcolepsy-treatment-safe-effective-in-patients-with-cardiovascularcardiometabolic-comorbidities/2470490/Study results presented at the 2024 SLEEP meeting of the Associated Professional Sleep Societies demonstrated that Xywav (low-sodium oxybate; Jazz Pharmaceuticals, Dublin, Ireland) treatment for narcolepsy was safe and effective for those with cardiovascular (CV) and cardiometabolic (CM) comorbid
- Large Scale Survey of Patients with MS Uncovers Significant Barriers to Care: 42% of Respondents Do Not See an MS Specialisthttps://practicalneurology.com/news/large-scale-survey-of-ms-patient-needs-uncovers-significant-barriers-to-care-42-do-not-see-an-ms-specialist/2470481/Results from a large-scale, national survey highlight the significant barriers that people living with multiple sclerosis (MS) face in accessing resources and health care in the United States. The top barriers identified from the survey commissioned by The Multiple Sclerosis Association of Americ
- Otsuka Terminates Development of Potential Agitation Treatment for Alzheimer Diseasehttps://practicalneurology.com/news/otsuka-terminates-development-of-potential-agitation-treatment-for-alzheimer-disease/2470478/Otsuka Pharmaceutical (Tokyo, Japan) has terminated the development of AVP-786, a potential treatment for agitation associated with Alzheimer disease, after the drug failed to meet its primary endpoint in a phase 3 clinical trial (NCT03393520). The trial evaluated the efficacy of AVP-786 compared
- New Insights into ARIA-E Risk from Donanemab Studieshttps://practicalneurology.com/news/new-insights-into-aria-e-risk-from-donanemab-studies/2470464/In an effort to understand more about amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapy, researchers analyzed pooled data from 3 studies involving donanemab (Eli Lilly and Company, Indianapolis, IN) therapy for individuals with early Alzheimer disease (AD):
- Long-Term Data Reveal CBD Treatment Linked to Significant Reductions in Focal-Onset Seizureshttps://practicalneurology.com/news/long-term-data-reveal-cbd-treatment-linked-to-significant-reductions-in-focal-onset-seizures/2470450/The use of cannabidiol (CBD) was associated with reductions in focal-onset seizure, including focal aware seizures (FAS), focal impaired awareness seizures (FIAS), and focal to bilateral tonic-clonic seizures (FBTCS), with an acceptable safety profile. These results of an analysis of a study popu
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- New Study Examines the Risk of Relapse in Those Discontinuing MS Therapyhttps://practicalneurology.com/news/new-study-examines-the-risk-of-relapse-in-those-discontinuing-ms-therapy/2470432/The discontinuation of high-efficacy therapies (HETs) that impact immune cell trafficking, including Tysabri (natalizumab; Biogen, Cambridge, MA) and Gilenya (fingolimod; Novartis, East Hanover, NJ), in people aged ≥50 years with nonactive multiple sclerosis (MS) was associated with a signific
- No Benefit Seen with Adding Blood Thinners to r-TPA for Ischemic Stroke Treatmenthttps://practicalneurology.com/news/adding-blood-thinners-to-r-tpa-for-ischemic-stroke-treatment-does-not-improve-outcomes/2470398/The addition of blood thinners to standard thrombolytic therapy for ischemic stroke did not significantly improve patient physical function compared with the use of thrombolysis alone, according to results of a large clinical trial presented at the American Stroke Association’s Internationa
- New Guidelines for Comprehensive Epilepsy Care Publishedhttps://practicalneurology.com/news/new-guidelines-for-specialized-epilepsy-care-centers-published/2470396/The National Association of Epilepsy Centers (NAEC) has published the first updated guidelines for specialized epilepsy centers in over a decade. The recommendations provide a comprehensive framework for delivering high-quality care for the estimated 3.4 million people in the United States living